Business Wire

ELECTREON

11.4.2022 09:02:16 CEST | Business Wire | Press release

Share
Electreon Announces Extension of World’s First Wireless Electric Road for Trucks and Buses

Electreon (TASE: ELWS.TA), the leading provider of wireless and in-road wireless electric vehicle (EV) charging technology, today announced the one year extension of the Smartroad Gotland pilot project in Sweden. The €2 million ($2.17 million) budget for the extension is funded by the Swedish Transport Administration and includes an upgrade of 400 m of the existing installation. Electreon will also extend the run of the electric airport shuttle bus—the shuttle will continue to undergo testing and simultaneously be available for commercial rides, and will open to the public in the summer of 2022. Government stakeholders, commercial fleet operators, and businesses interested in the technology are welcome to visit the project site and learn more about the project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005166/en/

“The team at Smartroad Gotland is excited for the one year extension of this project and for the opportunity to demonstrate the continued endurance of our wireless charging technology in Swedish weather,” said Håkan Sundelin, director of the Nordic Region at Electreon and project manager for Smartroad Gotland. “The planned large scale electric road pilot in Sweden, in addition to the French government’s decision to fund pilots for wireless charging roads, shows high demand for Electreon’s technology in Europe.''

Jan Pettersson, program manager of electrification, Swedish Transport Administration said, “We are very positive about the opportunity to test higher wireless charging performance, as well as road durability. Now that the corona restrictions have eased, we are also looking forward to spreading the knowledge from the project more widely.”

As part of the project extension, Electreon will increase the capacity of its receivers to transfer energy to approximately 30 kW and examine a new generation of its technology. This will demonstrate how the wireless charging infrastructure can be upgraded to meet evolving needs over time. Electreon will also deploy its software capabilities, such as its billing feature, which enables the Company to invoice vehicle subscribers using the Electric Road System.

After the upgrade is complete, the long-haul e-truck and commercial passenger e-bus, that have now been utilizing the wireless charging infrastructure for one year as part of this project, will undergo continued testing. The Swedish National Road and Transport Research Institute (VTI) will perform third-party endurance and stress tests to verify that Electreon’s technology and charging coils are unaffected by road construction and heavy-duty truck use. Electreon’s wireless charging technology is designed to be future proof, and this project will continue to prove that Electreon offers long-term performance with minimal maintenance. Additional third-party endurance tests of Electreon’s wireless charging technology are currently being performed as part of the BASt project in Germany and the Arena of the Future project in Italy.

To date, Electreon’s patented technology has been integrated with a wide range of vehicles, as part of its ongoing collaborations with auto manufacturers including Renault, Stellantis, Iveco, and Volkswagen. In February 2022, Electreon announced it was awarded a Michigan Department of Transportation (MDOT) contract for the first public Electric Road System for wireless EV charging in the U.S. In November 2021, Electreon’s wireless charging technology was named one of TIME’s 100 Best Inventions of 2021 .

About Electreon

Electreon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. Electreon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye